Priority review granted to bepirovirsen for chronic hepatitis B Infectious Disease Advisor 14:45 Wed, 29 Apr
CDC's new hepatitis B vaccine recommendations will cause more infant infections, studies find PhillyVoice 14:41 Wed, 29 Apr
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B Business Wire (Press Release) 07:07 Tue, 28 Apr
Mirum pharmaceuticals announces primary endpoint met in phase 2b portion of the azure-1 study of brelovitug in chronic hepatitis delta virus Business Wire (Press Release) 13:04 Mon, 27 Apr
Brii bio presents cross-study analysis of post-treatment HBsAg rebound at apasl 2026 PR Newswire (Press Release) 12:01 Sun, 26 Apr